Virios Therapeutics (VIRI) to Release Earnings on Monday

Virios Therapeutics (NASDAQ:VIRIGet Rating) will be releasing its earnings data before the market opens on Monday, November 14th. Analysts expect Virios Therapeutics to post earnings of ($0.49) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Virios Therapeutics (NASDAQ:VIRIGet Rating) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, analysts expect Virios Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Virios Therapeutics Price Performance

VIRI stock opened at $0.36 on Friday. The business has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $4.05. The firm has a market capitalization of $3.00 million, a PE ratio of -0.17 and a beta of 1.61. Virios Therapeutics has a 1 year low of $0.26 and a 1 year high of $9.11.

Institutional Investors Weigh In On Virios Therapeutics

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Virios Therapeutics by 63.4% in the first quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock valued at $1,082,000 after acquiring an additional 93,800 shares during the last quarter. UBS Group AG lifted its holdings in Virios Therapeutics by 528.3% in the first quarter. UBS Group AG now owns 14,137 shares of the company’s stock valued at $63,000 after acquiring an additional 11,887 shares during the last quarter. Finally, State Street Corp acquired a new position in Virios Therapeutics in the second quarter valued at approximately $45,000. 13.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered Virios Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 20th.

About Virios Therapeutics

(Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Read More

Earnings History for Virios Therapeutics (NASDAQ:VIRI)

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with's FREE daily email newsletter.